Symbiotec Pharmalab Ltd

Symbiotec Pharmalab Earnings Call Transcript: Key Takeaways

Symbiotec reported Q1 FY27 Revenue of ₹218 Cr, but underlying PAT remains soft due to heavy pre-operative expense drags from unmonetized new business segments.

Call

Guides 20% growth

Symbiotec Pharmalab Results Update

Symbiotec Pharmalab released its Q1FY27 investor update. The company reported consolidated revenue of Rs. 218.2 Crore and PAT of Rs. 14.1 Crore for the period.

Symbiotec Pharmalab Investor Presentation: Key Takeaways

Symbiotec Pharmalab Q1FY27 results show steady 7% revenue growth in core API business, offset by high opex/depreciation from significant new capex in Injectables and CDMO services.

Symbiotec Pharmalab Q1 FY27 Results: Net Profit ₹14.1 Cr, Down 52.8% YoY

Symbiotec Pharmalab Ltd reported revenue from operations of ₹218.2 Cr (+7.4% YoY) and net profit of ₹14.1 Cr (-52.8% YoY) for Q1 FY27.

Key figure

Net profit ₹14.1 Cr · -52.8% YoY

Symbiotec Pharmalab Board Meeting Date

Symbiotec Pharmalab Ltd scheduled a board meeting for September 21, 2026, to consider financial results for the quarter ended June 30, 2026.

Symbiotec Pharmalab Share Pledge

Symbiotec Pharmalab promoters pledged 34.93 lakh shares (~5.44%) to debenture trustee Beacon Trusteeship. This Securitisation encumbrance secures the company's debenture issue.

Symbiotec Pharmalab Capital Structure Change

Mirae Asset Mutual Fund acquired 34,97,420 shares of Symbiotec Pharmalab Ltd. This open market purchase increased their stake from 0.78% to 6.22%.